nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Anaemia—Hydroxyurea—psoriasis	0.00301	0.00301	CcSEcCtD
Oritavancin—Hyperuricaemia—Methotrexate—psoriasis	0.003	0.003	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Acitretin—psoriasis	0.00292	0.00292	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.00291	0.00291	CcSEcCtD
Oritavancin—Cardiac disorder—Mycophenolic acid—psoriasis	0.00291	0.00291	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Hydrocortisone—psoriasis	0.00287	0.00287	CcSEcCtD
Oritavancin—Blood uric acid increased—Methotrexate—psoriasis	0.00284	0.00284	CcSEcCtD
Oritavancin—Mediastinal disorder—Mycophenolic acid—psoriasis	0.00282	0.00282	CcSEcCtD
Oritavancin—Infestation NOS—Cyclosporine—psoriasis	0.00282	0.00282	CcSEcCtD
Oritavancin—Infestation—Cyclosporine—psoriasis	0.00282	0.00282	CcSEcCtD
Oritavancin—Dizziness—Methoxsalen—psoriasis	0.00282	0.00282	CcSEcCtD
Oritavancin—Hypersensitivity—Calcitriol—psoriasis	0.0028	0.0028	CcSEcCtD
Oritavancin—Infestation NOS—Mycophenolate mofetil—psoriasis	0.00275	0.00275	CcSEcCtD
Oritavancin—Infestation—Mycophenolate mofetil—psoriasis	0.00275	0.00275	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.00275	0.00275	CcSEcCtD
Oritavancin—Malnutrition—Mycophenolic acid—psoriasis	0.00273	0.00273	CcSEcCtD
Oritavancin—Pruritus—Calcitriol—psoriasis	0.00269	0.00269	CcSEcCtD
Oritavancin—Rash—Methoxsalen—psoriasis	0.00269	0.00269	CcSEcCtD
Oritavancin—Dermatitis—Methoxsalen—psoriasis	0.00269	0.00269	CcSEcCtD
Oritavancin—Urticaria—Acitretin—psoriasis	0.00269	0.00269	CcSEcCtD
Oritavancin—Headache—Methoxsalen—psoriasis	0.00267	0.00267	CcSEcCtD
Oritavancin—Infection—Hydroxyurea—psoriasis	0.00264	0.00264	CcSEcCtD
Oritavancin—Nervous system disorder—Hydroxyurea—psoriasis	0.0026	0.0026	CcSEcCtD
Oritavancin—Diarrhoea—Calcitriol—psoriasis	0.0026	0.0026	CcSEcCtD
Oritavancin—Skin disorder—Hydroxyurea—psoriasis	0.00258	0.00258	CcSEcCtD
Oritavancin—Nausea—Methoxsalen—psoriasis	0.00253	0.00253	CcSEcCtD
Oritavancin—Anaemia—Mycophenolic acid—psoriasis	0.00252	0.00252	CcSEcCtD
Oritavancin—Infestation—Hydrocortisone—psoriasis	0.00251	0.00251	CcSEcCtD
Oritavancin—Infestation NOS—Hydrocortisone—psoriasis	0.00251	0.00251	CcSEcCtD
Oritavancin—Hypersensitivity—Acitretin—psoriasis	0.00249	0.00249	CcSEcCtD
Oritavancin—Connective tissue disorder—Cyclosporine—psoriasis	0.00249	0.00249	CcSEcCtD
Oritavancin—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.00249	0.00249	CcSEcCtD
Oritavancin—Oedema peripheral—Mycophenolate mofetil—psoriasis	0.00243	0.00243	CcSEcCtD
Oritavancin—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.00243	0.00243	CcSEcCtD
Oritavancin—Vomiting—Calcitriol—psoriasis	0.00242	0.00242	CcSEcCtD
Oritavancin—Rash—Calcitriol—psoriasis	0.0024	0.0024	CcSEcCtD
Oritavancin—Dermatitis—Calcitriol—psoriasis	0.0024	0.0024	CcSEcCtD
Oritavancin—Pruritus—Acitretin—psoriasis	0.00239	0.00239	CcSEcCtD
Oritavancin—Pruritus—Fluocinolone Acetonide—psoriasis	0.00239	0.00239	CcSEcCtD
Oritavancin—Headache—Calcitriol—psoriasis	0.00238	0.00238	CcSEcCtD
Oritavancin—Myalgia—Mycophenolic acid—psoriasis	0.00232	0.00232	CcSEcCtD
Oritavancin—Diarrhoea—Acitretin—psoriasis	0.00231	0.00231	CcSEcCtD
Oritavancin—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00231	0.00231	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.0023	0.0023	CcSEcCtD
Oritavancin—Cardiac disorder—Mycophenolate mofetil—psoriasis	0.00229	0.00229	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00229	0.00229	CcSEcCtD
Oritavancin—Mediastinal disorder—Cyclosporine—psoriasis	0.00228	0.00228	CcSEcCtD
Oritavancin—Nausea—Calcitriol—psoriasis	0.00226	0.00226	CcSEcCtD
Oritavancin—Dizziness—Acitretin—psoriasis	0.00224	0.00224	CcSEcCtD
Oritavancin—Dizziness—Fluocinolone Acetonide—psoriasis	0.00223	0.00223	CcSEcCtD
Oritavancin—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.00223	0.00223	CcSEcCtD
Oritavancin—Connective tissue disorder—Hydrocortisone—psoriasis	0.00221	0.00221	CcSEcCtD
Oritavancin—Infection—Mycophenolic acid—psoriasis	0.00221	0.00221	CcSEcCtD
Oritavancin—Malnutrition—Cyclosporine—psoriasis	0.0022	0.0022	CcSEcCtD
Oritavancin—Nervous system disorder—Mycophenolic acid—psoriasis	0.00218	0.00218	CcSEcCtD
Oritavancin—Tachycardia—Mycophenolic acid—psoriasis	0.00217	0.00217	CcSEcCtD
Oritavancin—Skin disorder—Mycophenolic acid—psoriasis	0.00216	0.00216	CcSEcCtD
Oritavancin—Malnutrition—Mycophenolate mofetil—psoriasis	0.00215	0.00215	CcSEcCtD
Oritavancin—Vomiting—Acitretin—psoriasis	0.00215	0.00215	CcSEcCtD
Oritavancin—Vomiting—Fluocinolone Acetonide—psoriasis	0.00214	0.00214	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Prednisone—psoriasis	0.00214	0.00214	CcSEcCtD
Oritavancin—Rash—Acitretin—psoriasis	0.00213	0.00213	CcSEcCtD
Oritavancin—Dermatitis—Acitretin—psoriasis	0.00213	0.00213	CcSEcCtD
Oritavancin—Rash—Fluocinolone Acetonide—psoriasis	0.00213	0.00213	CcSEcCtD
Oritavancin—Dermatitis—Fluocinolone Acetonide—psoriasis	0.00212	0.00212	CcSEcCtD
Oritavancin—Headache—Acitretin—psoriasis	0.00212	0.00212	CcSEcCtD
Oritavancin—Headache—Fluocinolone Acetonide—psoriasis	0.00211	0.00211	CcSEcCtD
Oritavancin—Anaemia—Cyclosporine—psoriasis	0.00204	0.00204	CcSEcCtD
Oritavancin—Immune system disorder—Hydrocortisone—psoriasis	0.00203	0.00203	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.00203	0.00203	CcSEcCtD
Oritavancin—Angioedema—Cyclosporine—psoriasis	0.00201	0.00201	CcSEcCtD
Oritavancin—Nausea—Acitretin—psoriasis	0.00201	0.00201	CcSEcCtD
Oritavancin—Nausea—Fluocinolone Acetonide—psoriasis	0.002	0.002	CcSEcCtD
Oritavancin—Anaemia—Mycophenolate mofetil—psoriasis	0.00199	0.00199	CcSEcCtD
Oritavancin—Angioedema—Mycophenolate mofetil—psoriasis	0.00197	0.00197	CcSEcCtD
Oritavancin—Malnutrition—Hydrocortisone—psoriasis	0.00196	0.00196	CcSEcCtD
Oritavancin—Hypersensitivity—Hydroxyurea—psoriasis	0.00196	0.00196	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.00192	0.00192	CcSEcCtD
Oritavancin—Myalgia—Cyclosporine—psoriasis	0.00188	0.00188	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.00186	0.00186	CcSEcCtD
Oritavancin—Angioedema—Prednisolone—psoriasis	0.00183	0.00183	CcSEcCtD
Oritavancin—Myalgia—Mycophenolate mofetil—psoriasis	0.00183	0.00183	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.00182	0.00182	CcSEcCtD
Oritavancin—Diarrhoea—Hydroxyurea—psoriasis	0.00182	0.00182	CcSEcCtD
Oritavancin—Angioedema—Hydrocortisone—psoriasis	0.00179	0.00179	CcSEcCtD
Oritavancin—Infection—Cyclosporine—psoriasis	0.00179	0.00179	CcSEcCtD
Oritavancin—Nervous system disorder—Cyclosporine—psoriasis	0.00176	0.00176	CcSEcCtD
Oritavancin—Dizziness—Hydroxyurea—psoriasis	0.00176	0.00176	CcSEcCtD
Oritavancin—Skin disorder—Cyclosporine—psoriasis	0.00175	0.00175	CcSEcCtD
Oritavancin—Infection—Mycophenolate mofetil—psoriasis	0.00174	0.00174	CcSEcCtD
Oritavancin—Eosinophilia—Methotrexate—psoriasis	0.00173	0.00173	CcSEcCtD
Oritavancin—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.00172	0.00172	CcSEcCtD
Oritavancin—Tachycardia—Mycophenolate mofetil—psoriasis	0.00171	0.00171	CcSEcCtD
Oritavancin—Skin disorder—Mycophenolate mofetil—psoriasis	0.00171	0.00171	CcSEcCtD
Oritavancin—Vomiting—Hydroxyurea—psoriasis	0.00169	0.00169	CcSEcCtD
Oritavancin—Angioedema—Triamcinolone—psoriasis	0.00169	0.00169	CcSEcCtD
Oritavancin—Rash—Hydroxyurea—psoriasis	0.00167	0.00167	CcSEcCtD
Oritavancin—Dermatitis—Hydroxyurea—psoriasis	0.00167	0.00167	CcSEcCtD
Oritavancin—Myalgia—Hydrocortisone—psoriasis	0.00167	0.00167	CcSEcCtD
Oritavancin—Headache—Hydroxyurea—psoriasis	0.00166	0.00166	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.00166	0.00166	CcSEcCtD
Oritavancin—Connective tissue disorder—Prednisone—psoriasis	0.00165	0.00165	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.00164	0.00164	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.0016	0.0016	CcSEcCtD
Oritavancin—Tachycardia—Prednisolone—psoriasis	0.0016	0.0016	CcSEcCtD
Oritavancin—Infection—Hydrocortisone—psoriasis	0.00159	0.00159	CcSEcCtD
Oritavancin—Nausea—Hydroxyurea—psoriasis	0.00158	0.00158	CcSEcCtD
Oritavancin—Pruritus—Mycophenolic acid—psoriasis	0.00157	0.00157	CcSEcCtD
Oritavancin—Myalgia—Triamcinolone—psoriasis	0.00157	0.00157	CcSEcCtD
Oritavancin—Nervous system disorder—Hydrocortisone—psoriasis	0.00157	0.00157	CcSEcCtD
Oritavancin—Tachycardia—Hydrocortisone—psoriasis	0.00156	0.00156	CcSEcCtD
Oritavancin—Infestation NOS—Methotrexate—psoriasis	0.00156	0.00156	CcSEcCtD
Oritavancin—Infestation—Methotrexate—psoriasis	0.00156	0.00156	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00155	0.00155	CcSEcCtD
Oritavancin—Skin disorder—Hydrocortisone—psoriasis	0.00155	0.00155	CcSEcCtD
Oritavancin—Angioedema—Dexamethasone—psoriasis	0.00153	0.00153	CcSEcCtD
Oritavancin—Angioedema—Betamethasone—psoriasis	0.00153	0.00153	CcSEcCtD
Oritavancin—Diarrhoea—Mycophenolic acid—psoriasis	0.00152	0.00152	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00152	0.00152	CcSEcCtD
Oritavancin—Immune system disorder—Prednisone—psoriasis	0.00151	0.00151	CcSEcCtD
Oritavancin—Infection—Triamcinolone—psoriasis	0.0015	0.0015	CcSEcCtD
Oritavancin—Dizziness—Mycophenolic acid—psoriasis	0.00147	0.00147	CcSEcCtD
Oritavancin—Tachycardia—Triamcinolone—psoriasis	0.00147	0.00147	CcSEcCtD
Oritavancin—Malnutrition—Prednisone—psoriasis	0.00146	0.00146	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.00146	0.00146	CcSEcCtD
Oritavancin—Urticaria—Cyclosporine—psoriasis	0.00143	0.00143	CcSEcCtD
Oritavancin—Myalgia—Dexamethasone—psoriasis	0.00143	0.00143	CcSEcCtD
Oritavancin—Myalgia—Betamethasone—psoriasis	0.00143	0.00143	CcSEcCtD
Oritavancin—Vomiting—Mycophenolic acid—psoriasis	0.00141	0.00141	CcSEcCtD
Oritavancin—Rash—Mycophenolic acid—psoriasis	0.0014	0.0014	CcSEcCtD
Oritavancin—Dermatitis—Mycophenolic acid—psoriasis	0.0014	0.0014	CcSEcCtD
Oritavancin—Urticaria—Mycophenolate mofetil—psoriasis	0.00139	0.00139	CcSEcCtD
Oritavancin—Headache—Mycophenolic acid—psoriasis	0.00139	0.00139	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.00138	0.00138	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.00137	0.00137	CcSEcCtD
Oritavancin—Infection—Dexamethasone—psoriasis	0.00136	0.00136	CcSEcCtD
Oritavancin—Infection—Betamethasone—psoriasis	0.00136	0.00136	CcSEcCtD
Oritavancin—Anaemia—Prednisone—psoriasis	0.00135	0.00135	CcSEcCtD
Oritavancin—Nervous system disorder—Betamethasone—psoriasis	0.00134	0.00134	CcSEcCtD
Oritavancin—Nervous system disorder—Dexamethasone—psoriasis	0.00134	0.00134	CcSEcCtD
Oritavancin—Tachycardia—Dexamethasone—psoriasis	0.00133	0.00133	CcSEcCtD
Oritavancin—Tachycardia—Betamethasone—psoriasis	0.00133	0.00133	CcSEcCtD
Oritavancin—Angioedema—Prednisone—psoriasis	0.00133	0.00133	CcSEcCtD
Oritavancin—Hypersensitivity—Cyclosporine—psoriasis	0.00133	0.00133	CcSEcCtD
Oritavancin—Erythema multiforme—Methotrexate—psoriasis	0.00132	0.00132	CcSEcCtD
Oritavancin—Nausea—Mycophenolic acid—psoriasis	0.00132	0.00132	CcSEcCtD
Oritavancin—Urticaria—Prednisolone—psoriasis	0.0013	0.0013	CcSEcCtD
Oritavancin—Cardiac disorder—Methotrexate—psoriasis	0.0013	0.0013	CcSEcCtD
Oritavancin—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00129	0.00129	CcSEcCtD
Oritavancin—Pruritus—Cyclosporine—psoriasis	0.00127	0.00127	CcSEcCtD
Oritavancin—Urticaria—Hydrocortisone—psoriasis	0.00127	0.00127	CcSEcCtD
Oritavancin—Immune system disorder—Methotrexate—psoriasis	0.00126	0.00126	CcSEcCtD
Oritavancin—Mediastinal disorder—Methotrexate—psoriasis	0.00126	0.00126	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Betamethasone—psoriasis	0.00124	0.00124	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.00124	0.00124	CcSEcCtD
Oritavancin—Pruritus—Mycophenolate mofetil—psoriasis	0.00124	0.00124	CcSEcCtD
Oritavancin—Myalgia—Prednisone—psoriasis	0.00124	0.00124	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.00123	0.00123	CcSEcCtD
Oritavancin—Diarrhoea—Cyclosporine—psoriasis	0.00123	0.00123	CcSEcCtD
Oritavancin—Malnutrition—Methotrexate—psoriasis	0.00122	0.00122	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisolone—psoriasis	0.00121	0.00121	CcSEcCtD
Oritavancin—Diarrhoea—Mycophenolate mofetil—psoriasis	0.0012	0.0012	CcSEcCtD
Oritavancin—Urticaria—Triamcinolone—psoriasis	0.0012	0.0012	CcSEcCtD
Oritavancin—Dizziness—Cyclosporine—psoriasis	0.00119	0.00119	CcSEcCtD
Oritavancin—Infection—Prednisone—psoriasis	0.00118	0.00118	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Betamethasone—psoriasis	0.00118	0.00118	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00118	0.00118	CcSEcCtD
Oritavancin—Hypersensitivity—Hydrocortisone—psoriasis	0.00118	0.00118	CcSEcCtD
Oritavancin—Nervous system disorder—Prednisone—psoriasis	0.00117	0.00117	CcSEcCtD
Oritavancin—Tachycardia—Prednisone—psoriasis	0.00116	0.00116	CcSEcCtD
Oritavancin—Dizziness—Mycophenolate mofetil—psoriasis	0.00116	0.00116	CcSEcCtD
Oritavancin—Skin disorder—Prednisone—psoriasis	0.00116	0.00116	CcSEcCtD
Oritavancin—Vomiting—Cyclosporine—psoriasis	0.00114	0.00114	CcSEcCtD
Oritavancin—Rash—Cyclosporine—psoriasis	0.00113	0.00113	CcSEcCtD
Oritavancin—Dermatitis—Cyclosporine—psoriasis	0.00113	0.00113	CcSEcCtD
Oritavancin—Pruritus—Hydrocortisone—psoriasis	0.00113	0.00113	CcSEcCtD
Oritavancin—Headache—Cyclosporine—psoriasis	0.00113	0.00113	CcSEcCtD
Oritavancin—Anaemia—Methotrexate—psoriasis	0.00113	0.00113	CcSEcCtD
Oritavancin—Vomiting—Mycophenolate mofetil—psoriasis	0.00112	0.00112	CcSEcCtD
Oritavancin—Hypersensitivity—Triamcinolone—psoriasis	0.00111	0.00111	CcSEcCtD
Oritavancin—Rash—Mycophenolate mofetil—psoriasis	0.00111	0.00111	CcSEcCtD
Oritavancin—Dermatitis—Mycophenolate mofetil—psoriasis	0.00111	0.00111	CcSEcCtD
Oritavancin—Headache—Mycophenolate mofetil—psoriasis	0.0011	0.0011	CcSEcCtD
Oritavancin—Diarrhoea—Hydrocortisone—psoriasis	0.00109	0.00109	CcSEcCtD
Oritavancin—Urticaria—Betamethasone—psoriasis	0.00109	0.00109	CcSEcCtD
Oritavancin—Urticaria—Dexamethasone—psoriasis	0.00109	0.00109	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Prednisone—psoriasis	0.00108	0.00108	CcSEcCtD
Oritavancin—Dizziness—Prednisolone—psoriasis	0.00108	0.00108	CcSEcCtD
Oritavancin—Nausea—Cyclosporine—psoriasis	0.00107	0.00107	CcSEcCtD
Oritavancin—Pruritus—Triamcinolone—psoriasis	0.00107	0.00107	CcSEcCtD
Oritavancin—Dizziness—Hydrocortisone—psoriasis	0.00106	0.00106	CcSEcCtD
Oritavancin—Nausea—Mycophenolate mofetil—psoriasis	0.00104	0.00104	CcSEcCtD
Oritavancin—Myalgia—Methotrexate—psoriasis	0.00104	0.00104	CcSEcCtD
Oritavancin—Rash—Prednisolone—psoriasis	0.00103	0.00103	CcSEcCtD
Oritavancin—Dermatitis—Prednisolone—psoriasis	0.00103	0.00103	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00103	0.00103	CcSEcCtD
Oritavancin—Headache—Prednisolone—psoriasis	0.00103	0.00103	CcSEcCtD
Oritavancin—Vomiting—Hydrocortisone—psoriasis	0.00102	0.00102	CcSEcCtD
Oritavancin—Rash—Hydrocortisone—psoriasis	0.00101	0.00101	CcSEcCtD
Oritavancin—Dermatitis—Hydrocortisone—psoriasis	0.00101	0.00101	CcSEcCtD
Oritavancin—Headache—Hydrocortisone—psoriasis	0.001	0.001	CcSEcCtD
Oritavancin—Dizziness—Triamcinolone—psoriasis	0.000996	0.000996	CcSEcCtD
Oritavancin—Infection—Methotrexate—psoriasis	0.000988	0.000988	CcSEcCtD
Oritavancin—Nervous system disorder—Methotrexate—psoriasis	0.000975	0.000975	CcSEcCtD
Oritavancin—Nausea—Prednisolone—psoriasis	0.000973	0.000973	CcSEcCtD
Oritavancin—Pruritus—Betamethasone—psoriasis	0.000967	0.000967	CcSEcCtD
Oritavancin—Pruritus—Dexamethasone—psoriasis	0.000967	0.000967	CcSEcCtD
Oritavancin—Skin disorder—Methotrexate—psoriasis	0.000966	0.000966	CcSEcCtD
Oritavancin—Vomiting—Triamcinolone—psoriasis	0.000957	0.000957	CcSEcCtD
Oritavancin—Nausea—Hydrocortisone—psoriasis	0.00095	0.00095	CcSEcCtD
Oritavancin—Rash—Triamcinolone—psoriasis	0.000949	0.000949	CcSEcCtD
Oritavancin—Dermatitis—Triamcinolone—psoriasis	0.000949	0.000949	CcSEcCtD
Oritavancin—Urticaria—Prednisone—psoriasis	0.000945	0.000945	CcSEcCtD
Oritavancin—Headache—Triamcinolone—psoriasis	0.000943	0.000943	CcSEcCtD
Oritavancin—Diarrhoea—Dexamethasone—psoriasis	0.000935	0.000935	CcSEcCtD
Oritavancin—Diarrhoea—Betamethasone—psoriasis	0.000935	0.000935	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000906	0.000906	CcSEcCtD
Oritavancin—Dizziness—Dexamethasone—psoriasis	0.000904	0.000904	CcSEcCtD
Oritavancin—Dizziness—Betamethasone—psoriasis	0.000904	0.000904	CcSEcCtD
Oritavancin—Nausea—Triamcinolone—psoriasis	0.000894	0.000894	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisone—psoriasis	0.000877	0.000877	CcSEcCtD
Oritavancin—Vomiting—Dexamethasone—psoriasis	0.000869	0.000869	CcSEcCtD
Oritavancin—Vomiting—Betamethasone—psoriasis	0.000869	0.000869	CcSEcCtD
Oritavancin—Rash—Dexamethasone—psoriasis	0.000862	0.000862	CcSEcCtD
Oritavancin—Rash—Betamethasone—psoriasis	0.000862	0.000862	CcSEcCtD
Oritavancin—Dermatitis—Betamethasone—psoriasis	0.000861	0.000861	CcSEcCtD
Oritavancin—Dermatitis—Dexamethasone—psoriasis	0.000861	0.000861	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Methotrexate—psoriasis	0.000859	0.000859	CcSEcCtD
Oritavancin—Headache—Betamethasone—psoriasis	0.000856	0.000856	CcSEcCtD
Oritavancin—Headache—Dexamethasone—psoriasis	0.000856	0.000856	CcSEcCtD
Oritavancin—Pruritus—Prednisone—psoriasis	0.000842	0.000842	CcSEcCtD
Oritavancin—Diarrhoea—Prednisone—psoriasis	0.000814	0.000814	CcSEcCtD
Oritavancin—Nausea—Betamethasone—psoriasis	0.000812	0.000812	CcSEcCtD
Oritavancin—Nausea—Dexamethasone—psoriasis	0.000812	0.000812	CcSEcCtD
Oritavancin—Urticaria—Methotrexate—psoriasis	0.00079	0.00079	CcSEcCtD
Oritavancin—Dizziness—Prednisone—psoriasis	0.000787	0.000787	CcSEcCtD
Oritavancin—Vomiting—Prednisone—psoriasis	0.000757	0.000757	CcSEcCtD
Oritavancin—Rash—Prednisone—psoriasis	0.00075	0.00075	CcSEcCtD
Oritavancin—Dermatitis—Prednisone—psoriasis	0.00075	0.00075	CcSEcCtD
Oritavancin—Headache—Prednisone—psoriasis	0.000745	0.000745	CcSEcCtD
Oritavancin—Hypersensitivity—Methotrexate—psoriasis	0.000733	0.000733	CcSEcCtD
Oritavancin—Nausea—Prednisone—psoriasis	0.000707	0.000707	CcSEcCtD
Oritavancin—Pruritus—Methotrexate—psoriasis	0.000704	0.000704	CcSEcCtD
Oritavancin—Diarrhoea—Methotrexate—psoriasis	0.00068	0.00068	CcSEcCtD
Oritavancin—Dizziness—Methotrexate—psoriasis	0.000658	0.000658	CcSEcCtD
Oritavancin—Vomiting—Methotrexate—psoriasis	0.000632	0.000632	CcSEcCtD
Oritavancin—Rash—Methotrexate—psoriasis	0.000627	0.000627	CcSEcCtD
Oritavancin—Dermatitis—Methotrexate—psoriasis	0.000626	0.000626	CcSEcCtD
Oritavancin—Headache—Methotrexate—psoriasis	0.000623	0.000623	CcSEcCtD
Oritavancin—Nausea—Methotrexate—psoriasis	0.000591	0.000591	CcSEcCtD
